


What is claimed is:

1. Use of sotorasib in the manufacture of a medicament for treating cancer in a patient, wherein the use comprises that a therapeutically effective amount of sotorasib is to be administered to the patient, wherein the patient had moderate or severe hepatic
5 impairment prior to administration of the sotorasib, wherein sotorasib is a compound of



Formula (I)

(I).

2. The use of claim 1, wherein the patient had moderate hepatic impairment prior to administration of the sotorasib.

3. The use of claim 1, wherein the patient had severe hepatic impairment prior to
10 administration of the sotorasib.

4. The use of claim 1 or claim 2, wherein the use further comprises a step of determining whether the patient has moderate hepatic impairment.

5. The use of claim 1 or claim 3, wherein the use further comprises a step of determining whether the patient has severe hepatic impairment.

15 6. The use of any one of claims 1 to 5, wherein the therapeutically effective amount of sotorasib is 240 mg to 960 mg daily.

7. The use of any one of claims 1 to 6, wherein the therapeutically effective amount of sotorasib is 240 mg sotorasib daily.

8. The use of any one of claims 1 to 6, wherein the therapeutically effective
20 amount of sotorasib is 480 mg daily.

9. The use of any one of claims 1 to 6, wherein the therapeutically effective amount of sotorasib is 960 mg daily.

10. The use of any one of claims 1 to 9, wherein the patient has a cancer comprising a *KRAS G12C* mutation.

11. The use of claim 10, wherein the use further comprises determining whether the patient has a cancer comprising a *KRAS G12C* mutation.

5 12. The use of any one of claims 1 to 11, wherein the cancer is a solid tumor.

13. The use of any one of claims 1 to 11, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, 10 bladder cancer, myelodysplastic/myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, melanoma, ampullary cancer, gastric cancer, sinonasal cancer, or bile duct cancer.

14. The use of any one of claims 1 to 11, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown 15 primary, endometrial cancer, pancreatic cancer, melanoma, ampullary cancer, gastric cancer, sinonasal cancer, or bile duct cancer.

15. The use of any one of claims 1 to 11, wherein the cancer is non-small cell lung cancer.

16. The use of claim 15, wherein the non-small cell lung cancer is locally 20 advanced or metastatic.

17. The use of any one of claims 1 to 11, wherein the cancer is colorectal cancer.


18. The use of any one of claims 1 to 11, wherein the cancer is pancreatic cancer.

19. The use of any one of claims 1 to 18, where the sotorasib is to be administered as one or more tablets.

25 20. The use of any one of claims 1 to 19, wherein the sotorasib is to be administered orally.

21. The use of any one of claims 1 to 20, wherein the sotorasib is to be administered once daily.

22. Use of sotorasib in the manufacture of a medicament for treating cancer in a patient, wherein the use comprises that a therapeutically effective amount of sotorasib is to be administered to the patient, wherein the patient had moderate or severe hepatic impairment prior to administration of the sotorasib, wherein sotorasib is a compound of



Formula (I)

(I);

wherein the patient has a cancer comprising a *KRAS G12C* mutation;

wherein the cancer is non-small cell lung cancer or colorectal cancer; and

10 wherein the therapeutically effective amount is 960 mg of sotorasib once daily.

23. The use of claim 22, wherein the patient had moderate hepatic impairment prior to administration of the sotorasib.

24. The use of claim 22, wherein the patient had severe hepatic impairment prior to administration of the sotorasib.